MX2024001889A - Compuestos deuterados. - Google Patents

Compuestos deuterados.

Info

Publication number
MX2024001889A
MX2024001889A MX2024001889A MX2024001889A MX2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A MX 2024001889 A MX2024001889 A MX 2024001889A
Authority
MX
Mexico
Prior art keywords
deuterated compounds
compounds
deuterated
formula
disclosed
Prior art date
Application number
MX2024001889A
Other languages
English (en)
Spanish (es)
Inventor
Chutian Shu
Jin Tian
Original Assignee
Alebund Pharmaceuticals Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alebund Pharmaceuticals Hong Kong Ltd filed Critical Alebund Pharmaceuticals Hong Kong Ltd
Publication of MX2024001889A publication Critical patent/MX2024001889A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2024001889A 2021-08-13 2022-08-09 Compuestos deuterados. MX2024001889A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021112521 2021-08-13
CN2022106648 2022-07-20
PCT/CN2022/111089 WO2023016440A1 (en) 2021-08-13 2022-08-09 Deuterated compounds

Publications (1)

Publication Number Publication Date
MX2024001889A true MX2024001889A (es) 2024-02-29

Family

ID=85199822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001889A MX2024001889A (es) 2021-08-13 2022-08-09 Compuestos deuterados.

Country Status (11)

Country Link
US (1) US20240270731A1 (https=)
EP (1) EP4384507A4 (https=)
JP (1) JP2024532807A (https=)
KR (1) KR20240047401A (https=)
CN (1) CN116848095B (https=)
AR (1) AR126778A1 (https=)
CA (1) CA3227149A1 (https=)
IL (1) IL310176A (https=)
MX (1) MX2024001889A (https=)
TW (1) TW202320762A (https=)
WO (1) WO2023016440A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐
TW202547458A (zh) * 2024-03-26 2025-12-16 香港商禮邦醫藥(香港)有限公司 用於治療體染色體顯性多囊性腎病之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60211891T2 (de) * 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
JP7618384B2 (ja) * 2017-02-21 2025-01-21 ジェンフィ Pparアゴニストとfxrアゴニストとの組合せ
CN109265380A (zh) * 2017-10-18 2019-01-25 深圳市塔吉瑞生物医药有限公司 取代的丙-2-烯-1-酮化合物及其药物组合物
WO2020156683A1 (en) * 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
CN112209896B (zh) * 2019-07-10 2023-05-16 苏州泽璟生物制药股份有限公司 噻唑烷二酮衍生物以及包含其的药物组合物
CN118480034B (zh) * 2023-02-13 2025-02-11 礼邦医药(香港)有限公司 氘代化合物的晶型或盐

Also Published As

Publication number Publication date
TW202320762A (zh) 2023-06-01
CA3227149A1 (en) 2023-02-16
AR126778A1 (es) 2023-11-15
US20240270731A1 (en) 2024-08-15
EP4384507A4 (en) 2025-06-18
CN116848095A (zh) 2023-10-03
EP4384507A1 (en) 2024-06-19
JP2024532807A (ja) 2024-09-10
WO2023016440A1 (en) 2023-02-16
AU2022327461A1 (en) 2024-02-01
KR20240047401A (ko) 2024-04-12
CN116848095B (zh) 2024-05-24
IL310176A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
GEP20146125B (en) Aminopyrimidines as syk inhibitors
WO2018226622A8 (en) Compounds for treating huntington's disease
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
AU2020231934A8 (en) Compounds useful in HIV therapy
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
DE602004024213D1 (en) Aminopropanolderivate
MX2022012239A (es) Compuestos de amida y usos de los mismos.
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
PH12022552177A1 (en) Heteroaryl heterocyclic compounds and uses thereof
MX2024001889A (es) Compuestos deuterados.
EP4643954A3 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2024002872A (es) Compuestos clorados de tetralina y composiciones farmaceuticas.
MX2025012133A (es) Derivados de tiadiazolona, composiciones y usos de estos
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
MX2023009190A (es) Compuestos triciclicos y usos de los mismos.
WO2021214348A3 (de) Verbindungen für elektronische vorrichtungen
ZA202401345B (en) Polypeptide drug conjugate having novel structure and application thereof
PH12021552779A1 (en) Amorphous pi3k inhibitor and pharmaceutical composition comprising same
MX2023001979A (es) Compuestos de pirimidinona y usos de los mismos.